Prestodiag Raises 2.2 Million Euros to Market Its Innovative Solutions for Microbiological Analysis

Online, June 10, 2014 (Newswire.com) - Prestodiag, a French company focused on Life Sciences, based in Villejuif, close to Paris (France), announces a 2.2 million Euros Series A financing round (3 million USD) from seed funds ATI (Amorcage Technologique Investissement, managed by CEA Investissement), Cap Decisif Management and Kreizig Invest, as well as from Go Beyond network and historical shareholders.

"This additional capital will allow us to accelerate our growth and develop our technological platform." said Thibaut Mercey, founding CEO, "We are at the edge of launching our first commercial product by the end of 2014, with other launches scheduled in 2015. This funding is key for Prestodiag to address the microbiological testing market and the team is enthusiastic about it."

Prestodiag has developed an innovative and proprietary optical method (PlasmIATM or "Plasmonic ImmunoAssay") for multiplex detection of bacteria. It allows a simple, direct and rapid detection of pathogens like Salmonella, Listeria or Escherichia coli, especially in food safety applications. In the future, Prestodiag will market a complete portfolio of assays on the platform, as well as innovations in multi-detection of pathogens and quantification.

"Prestodiag gathers an experienced and complementary team, who has already introduced its products to prominent food manufacturers. They have confirmed their needs for disruptive solutions, as the ones developed by Prestodiag", tells Celia Hart, investment Director, CEA Investissement.

"Prestodiag fits perfectly to our investment strategy" adds Catherine Boule from CapDecisif Management. "An impressive growth potential, a disruptive technology and a talented & balanced team".

Prestodiag also announces that Olivier Pasquier, a seasoned sales manager, joins the management team, and will be in charge of Sales, Marketing & Business Development.

About Prestodiag (www.prestodiag.com)
Prestodiag, based in Villejuif, close to Paris (France), is a young company specialized in development, production and commercialization of innovative optical solutions for Life Sciences. Its optical proprietary technology, "Plasmonic ImmunoAssay" (PlasmIATM), allows to perform multiplex, direct and label-free analyses, for bacterial detection in complex samples. This technology strongly reduces time-to-results, along with simplification and reduced costs.

About CapDecisif Management (www.capdecisif.com)
CapDecisif Management manages different investment vehicles mostly aimed at early-stage start-ups, the last announced in early 2014 being FCPR CapDecisif 3. Since 2002, the management team has invested in more than 50 companies in IT, Software, Life Sciences, Biotechnologies, Energy, Environment, Engineering. CapDecisif Management currently manages around 105 MЂ.

About CEA Investissement (www.cea-investissement.com)
Founded in 1999, CEA Investissement, a subsidiary of the CEA, is a specialist in seed investment in high-tech companies. It has more than 65MЂ under management, split into 2 vehicles: Fonds Stratйgique CEA and ATI - Amorзage technologique Investissement. Since its inception, CEA Investissement has financed more than 50 start-ups, in domains related to CEA expertise: Microelectronics, Life Sciences, Energy and Environment, Material Sciences, Instrumentation and Industrial in-vehicle systems. CEA-Investissement is based in Paris & Grenoble, France.

About Kreizig Invest
Kreizig Invest is an investment company created and led by Alain Le Roch, founder of the AES-Chemunex Group, currently a subsidiary of bioMйrieux since 2011. Kreizig Investment supports innovative companies in different sectors. Alain le Roch is also the President of the biotech cluster CapBiotek Bretagne.

About Go Beyond (http://www.go-beyond.biz/)
Go Beyond offers cross border investment opportunities, syndication/pooling, due diligence, investment monitoring services to individual investors, family offices, professional groups/associations and corporations. Go Beyond Network gathers a team of seasoned entrepreneurs and general managers who are now business angels.

Contact
Thibaut MERCEY
President
Tel: +33(0)1 46 58 43 04
pr@prestodiag.com